Outlook Therapeutics, Inc. (OTLK)Healthcare | Biotechnology | Iselin, United States | NasdaqCM
0.64 USD
+0.00
(0.593%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.64 0.00 (-0.005%) ⇩ (Aug. 28, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:52 a.m. EDT
The investment case here is bifurcated between a desperate short-term catalyst play and a fundamentally broken long-term story. On the short end, the stock is trading near its 200-day average but remains significantly below the $1.00 strike where massive option open interest creates a magnet effect. The recent price action shows volatility, dropping from highs near $1.15 to current levels, suggesting the market is digesting the mixed news of FDA approvals versus looming Nasdaq compliance and funding issues. The 'strong buy' analyst recommendation appears disconnected from the reality of negative revenue growth and a deteriorating balance sheet. On the long end, the fundamentals are catastrophic. The company has lost 99.57% of its value over the last nine years, with the trailing twelve months showing negative revenue and operating margins so deep they are mathematically undefined. The business is burning cash with no path to profitability visible in the data. While the FDA approvals for Lytenava are a positive milestone, they do not yet translate into the sustained revenue growth required to justify a premium valuation. The market is currently pricing in a high probability of delisting or further dilution, making this a speculative gamble rather than an investment. The lack of dividends and the eroding book value confirm that capital preservation is impossible here. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.403767 |
| MSTL | 0.879606 |
| AutoARIMA | 1.236919 |
| AutoTheta | 1.288506 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 100.25 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.153 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | -0.014 |
| Market Cap | 156,499,536 |
| Forward P/E | -4.61 |
| Beta | 0.80 |
| Website | https://outlooktherapeutics.com |
As of Aug. 22, 2026, 2:52 a.m. EDT: Options activity reveals a distinct 'pinning' bias at the $1.00 strike across nearly all expirations, with massive open interest relative to volume. This suggests market participants are positioning for a binary event or regulatory decision around that level, likely the upcoming FDA date mentioned in news. However, the sheer volume of out-of-the-money calls indicates speculative hope for a rally, while the heavy put open interest at $1.00 acts as a significant resistance ceiling. Implied volatility is elevated, reflecting uncertainty surrounding the company's compliance status and funding pressures.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.25862068 |
| Address1 | 111 S. Wood Avenue |
| Address2 | Unit #100 |
| All Time High | 878.4 |
| All Time Low | 0.161 |
| Ask | 0.6519 |
| Ask Size | 2 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 21,577,650 |
| Average Daily Volume3 Month | 18,673,849 |
| Average Volume | 18,673,849 |
| Average Volume10Days | 21,577,650 |
| Beta | 0.804 |
| Bid | 0.64 |
| Bid Size | 1 |
| Book Value | -0.056 |
| City | Iselin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6449 |
| Current Ratio | 0.808 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.6583 |
| Day Low | 0.6191 |
| Display Name | Outlook Therapeutics |
| Dividend Date | 1,552,867,200 |
| Earnings Call Timestamp End | 1,786,710,600 |
| Earnings Call Timestamp Start | 1,786,710,600 |
| Earnings Timestamp | 1,786,710,600 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda | -55,531,736 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.957 |
| Enterprise To Revenue | -141.118 |
| Enterprise Value | 164,188,400 |
| Eps Current Year | -0.42 |
| Eps Forward | -0.14 |
| Eps Trailing Twelve Months | -0.71 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2027 |
| Fifty Day Average Change | -0.5578 |
| Fifty Day Average Change Percent | -0.4637898 |
| Fifty Two Week Change Percent | -25.862068 |
| Fifty Two Week High | 2.538 |
| Fifty Two Week High Change | -1.8931 |
| Fifty Two Week High Change Percent | -0.74590224 |
| Fifty Two Week Low | 0.161 |
| Fifty Two Week Low Change | 0.4839 |
| Fifty Two Week Low Change Percent | 3.0055902 |
| Fifty Two Week Range | 0.161 - 2.538 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,465,911,000,000 |
| Float Shares | 196,109,177 |
| Forward Eps | -0.14 |
| Forward P E | -4.6064286 |
| Free Cashflow | -37,357,632 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Fullday Change | 0.00380003 |
| Fullday Change Percent | 0.592737 |
| Fullday Price | 0.64 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -2,275,914 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12639 |
| Held Percent Institutions | 0.08454 |
| Implied Shares Outstanding | 242,672,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,710,374,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. |
| Long Name | Outlook Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 156,499,536 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_145859589 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -61,123,256 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 155,577,374 |
| Number Of Analyst Opinions | 4 |
| Open | 0.65 |
| Operating Cashflow | -56,154,884 |
| Operating Margins | -1,242.5527 |
| Payout Ratio | 0.0 |
| Phone | 609 619 3990 |
| Post Market Change | -0.0049000382 |
| Post Market Change Percent | -0.7598136 |
| Post Market Price | 0.64 |
| Post Market Time | 1,787,961,226 |
| Previous Close | 0.6411 |
| Price Eps Current Year | -1.5354763 |
| Price Hint | 4 |
| Price To Book | -11.516071 |
| Price To Sales Trailing12 Months | -134.50975 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.449 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.00380003 |
| Regular Market Change Percent | 0.592737 |
| Regular Market Day High | 0.6583 |
| Regular Market Day Low | 0.6191 |
| Regular Market Day Range | 0.6191 - 0.6583 |
| Regular Market Open | 0.65 |
| Regular Market Previous Close | 0.6411 |
| Regular Market Price | 0.6449 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 9,482,025 |
| Return On Assets | -1.43166 |
| Revenue Growth | -0.994 |
| Revenue Per Share | -0.014 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 242,672,554 |
| Shares Percent Shares Out | 0.081999995 |
| Shares Short | 19,899,576 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,240,969 |
| Short Name | Outlook Therapeutics, Inc. |
| Short Percent Of Float | 0.086899996 |
| Short Ratio | 0.97 |
| Source Interval | 15 |
| State | NJ |
| Symbol | OTLK |
| Target High Price | 10.0 |
| Target Low Price | 1.6 |
| Target Mean Price | 4.9 |
| Target Median Price | 4.0 |
| Total Cash | 11,242,068 |
| Total Cash Per Share | 0.046 |
| Total Debt | 18,431,144 |
| Total Revenue | -1,163,481 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.88535 |
| Two Hundred Day Average Change | -0.24044997 |
| Two Hundred Day Average Change Percent | -0.27158746 |
| Type Disp | Equity |
| Volume | 9,482,025 |
| Website | https://outlooktherapeutics.com |
| Zip | 8,830 |